Larimar Therapeutics (LRMR) Operating Leases (2019 - 2025)

Larimar Therapeutics' Operating Leases history runs 7 years deep, the most recent figure standing at $3.0 million for Q4 2025.

• Quarterly Operating Leases fell 26.99% year-over-year to $3.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.0 million (down 26.99% YoY) and the FY2025 annual result came in at $3.0 million, down 26.99% from the prior year.
• Operating Leases was $3.0 million for Q4 2025 at Larimar Therapeutics, down from $3.2 million in the prior quarter.
• Across five years, Operating Leases topped out at $5.9 million in Q1 2021 and bottomed at $3.0 million in Q4 2025.
• A 5-year average of $4.6 million and a median of $4.7 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2024 — Operating Leases advanced 2.04% — and 2025, when it declined 26.99%.
• Larimar Therapeutics' Operating Leases stood at $5.4 million in 2021, then decreased by 11.3% to $4.8 million in 2022, then fell by 1.83% to $4.7 million in 2023, then fell by 13.85% to $4.1 million in 2024, then retreated by 26.99% to $3.0 million in 2025.
• Business Quant data shows LRMR's Operating Leases at $3.0 million in Q4 2025, $3.2 million in Q3 2025, and $3.5 million in Q2 2025.